Gland Pharma Limited has informed the Exchange regarding 'The 48th AGM of the Company will be held on August 25, 2026'.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gland Pharma Limited reported strong consolidated financial results for FY26 ended March 31, 2026. Total income was Rs 67,469.78 million with profit after tax of Rs 14,583.03 million, nearly doubling from Rs 7,539.13 million in FY25. Earnings per share (EPS) improved to Rs 62.35 from Rs 42.40 year-on-year. The Board recommended a final dividend of Rs 20 per equity share (2000% on face value of Rs 1), subject to shareholder approval at the 48th AGM scheduled for August 25, 2026. The record date for dividend eligibility is August 11, 2026. Auditors Deloitte Haskins & Sells issued an unmodified (clean) opinion on the annual financial statements. An exceptional charge of Rs 243.46 million was recorded due to new labour code provisions.
The company delivered near-doubled profit growth, indicating strong operational performance. The clean audit and robust dividend payout signal financial health, which could positively impact investor sentiment. Shareholders should note the August 11 record date to be eligible for the Rs 20 dividend.